The Peripheral and Central Nervous System Drug Advisory Committee (PCNSDAC) of the US Food and Drug Administration (FDA) makes recommendations for the approval or denial of drugs that treat nervous system diseases. Before issuing recommendations, the PCNSDAC hears public testimony about these drugs in an open forum.
1 For example, eteplirsen, a treatment for Duchenne muscular dystrophy, was approved after 52 public speakers provided testimony at the PCNSDAC meeting. 2 After approval of eteplirsen, critics spoke out against its approval, citing weak evidence from a 12-patient trial based on a surrogate end point. 3 Because public speakers overwhelmingly spoke in favor of eteplirsen, 3 critics raised concerns regarding the influence of public testimony on FDA drug approval.
4
In the interest of all patients, conflicts of interest (COI) among public speakers must be mitigated to ensure the ethical approval of drugs. Without addressing public speaker COIs, the integrity of new drug approvals may be compromised. Recent evaluations of public speaker COIs reported that pharmaceutical companies often pay traveling and lodging expenses for them. 5, 6 The aim of this study was to evaluate public PCNSDAC speakers to determine the proportion with an industry COI and the association of those COIs with the speaker's statements about the drug.
Methods | We based our methods on previous studies. a Some speakers declared a conflict of interest, had the disease, and took the drug and may be counted more than once in the last 3 columns.
investigators (W.A., J.A.): the public speaker's name, the organization that he or she represented, the drug being discussed, whether the speaker had the disease for which the drug was indicated, whether the speaker took the drug, the speaker's disclosed COIs, and whether his or her statements about the drug were positive, neutral, or negative. This study used publicly available data and was therefore exempt from institutional review board approval. Logistic regression was used to examine the association between declaring a COI and having the disease for which the drug is indicated and positive statements about the drug. We attempted to include a third variable (whether the speaker took the drug) but were not able to because no patients who took the drug spoke negatively. Stata statistical software, version 15.1 (StataCorp) was used for data analysis.
Results | We identified 226 public speakers from 17 meetings ( Table 1 and Discussion | Our results suggest that public speakers at PCNS-DAC meetings are more likely to provide positive statements about a drug if they have an industry COI or take the drug in question but not more likely if they have the disease for which the drug is indicated. These findings are consistent with previous studies. 5, 6 This study is limited by the use of only publicly available meeting transcripts. Thus, our analysis may exclude potential confounding variables. Given the proportion of patients who disclosed a COI and the association between COIs and positive statements, the acceptability of industry influence in gathering public speakers should be questioned. Of note, a significant portion of speakers did not mention COIs at all. Given the possibility that public speakers are capable of swaying approval committee opinion about a drug, declaring or denying COIs should be required.
